Skip to main content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Prescription Drugs & Other Medical Products


Displaying 21 - 30 of 120. 10 per page. Page 3.

Advanced Search

Medicare FFS Part B and International Drug Prices: A Comparison of the Top 50 Drugs

November 19, 2020
The September 13, 2020 Executive Order on Lowering Drug Prices by Putting America First declared, “It is the policy of the United States that the Medicare program should not pay more for costly Part B or Part D prescription drugs or biological products than the most-favored-nation price.” The Most Favored Nation (MFN) Model issued by the Centers for Medicare & Medicaid Services (CMS) on No

Comparing Insulin Prices in the U.S. to Other Countries

September 23, 2020
Insulin prices have increased dramatically over the past decade in the United States. This report presents results from international price comparisons of insulins using a price index approach.

Models for Medication-Assisted Treatment for Opioid Use Disorder, Retention, and Continuity of Care

July 8, 2020
Treatment providers, policymakers, and others are seeking ways to reverse the tide of mortality and morbidity that has accompanied the opioid epidemic. There are evidence-based treatments for opioid use disorder (OUD), including medication-assisted treatment (MAT) using buprenorphine, methadone, and naltrexone. Research shows that retention in MAT results in better outcomes.

Availability of Treatment for Opioid Use Disorder in Areas of High Foster Care Increases

April 26, 2020
Parental opioid use disorder (OUD) is a risk factor for the maltreatment of children and placement into foster care. Opioid agonist therapy (OAT) is an evidence-based treatment for OUD using medications such as methadone and buprenorphine. OAT can help parents enter recovery and reduce the risk of maltreatment, and potentially improve child welfare outcomes.

Addressing the Opioid Epidemic with Better Data: An Overview of HHS Priorities and Projects to Expand Data Capacity for Patient-Centered Outcomes Research on Opioids

October 30, 2019
This report builds on a workshop sponsored by ASPE, titled Addressing the Opioid Epidemic: Harnessing the Power of Data for Patient-Centered Research in December 2018, which showcased projects working to build the data infrastructure for patient-centered outcomes research around opioids.
Report to Congress

Report to Congress: Prescription Drugs: Innovation, Spending, and Patient Access

September 25, 2019
This Report responded to a request from the House and Senate Committees on Appropriations.
Report to Congress

Report to Congress: Prescription Drug Pricing Report

September 25, 2019
The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations.

Non-Fatal Opioid Overdose and Associated Health Outcomes: Final Summary Report

September 3, 2019
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO.
ASPE Issue Brief

Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief

July 7, 2019
Westat Printer Friendly Version in PDF Format (3 PDF pages)

Psychosocial Supports in Medication-Assisted Treatment: Site Visit Findings and Conclusions

July 7, 2019
The purpose of this report is to gain a better understanding of the role and range of different models of psychosocial support in medication-assisted treatment for opioid use disorder.